This event has passed.

Big In Japan Series: Dr. Naveed Shams, President and CEO of Santen Inc.: “Globalization at a Japanese Pharmaceutical Leader”

Name: Big In Japan Series: Dr. Naveed Shams, President and CEO of Santen Inc.: “Globalization at a Japanese Pharmaceutical Leader”
Start: 2014-04-16T18:00:00+00:00
End: 2014-04-16T21:00:00+00:00
Location: Sollicitudin Etiam – Black

April 16, 2014 @ 6:00 pm - 9:00 pm

$10 – $20

The first of our series featuring senior level executives with deep ties to Japan. Santen Inc. is the U.S. subsidiary of Japan’s Santen Ltd., a leader in the ophthalmological field.
In his four years at the prominent Japanese pharmaceutical company Santen, our speaker has been promoted twice and is currently President and CEO of the company’s U.S. operations as well as Chief Scientific Officer for the company globally. Dr. Shams will discuss his groundbreaking role within the company, including what approaches have enabled him to be effective as a non-Japanese executive operating at a senior level within a Japanese organization. Dr. Shams will also discuss how Santen is increasing its global presence, the importance of the U.S. organization in Santen’s globalization initiatives, and the challenges faced by Japanese pharmaceutical companies as they operate more globally.
Naveed Shams, M.D., Ph.D.
Santen Ltd. Dr. Shams joined Santen in 2010 as the Vice President of Clinical Affairs. In 2011 he was made head of Global Clinical Development & Medical Affairs in the Santen Global Research & Development Division. In his 17 years of experience in global drug development, he has played a significant and critical role in bringing three products to market, including Zaditor®/Zaditen®, Rescula®, and Lucentis®. He also supported the post-marketing efforts for Visudyne®. His industry experience spans companies such as Genentech, Novartis, OPKO Health, Storz Ophthalmics, and most recently On Demand Therapeutics, a drug delivery start-up in the San Francisco Bay area where he was President and Chief Medical Officer. While at Genentech, Dr. Shams led the clinical team in the development and approval of ranibizumab (Lucentis®). Dr. Shams received his medical degree from Dow Medical College in Karachi, Pakistan, and his PhD from the University of South Carolina in microbiology and immunology. He completed fellowships in cornea and external diseases at Harvard Medical School and histocompatibility and immunogenetics at Massachusetts General Hospital. Dr. Shams was formerly on faculty at Schepens Eye Research Institute and the Department of Ophthalmology at Harvard Medical School.In March of 2013, Dr. Shams was appointed President and CEO of Santen Inc., and Chief Scientific Officer of Santen Ltd. Dr. Shams joined Santen in 2010 as the Vice President of Clinical Affairs. In 2011 he was made head of Global Clinical Development & Medical Affairs in the Santen Global Research & Development Division. In his 17 years of experience in global drug development, he has played a significant and critical role in bringing three products to market, including Zaditor®/Zaditen®, Rescula®, and Lucentis®. He also supported the post-marketing efforts for Visudyne®. His industry experience spans companies such as Genentech, Novartis, OPKO Health, Storz Ophthalmics, and most recently On Demand Therapeutics, a drug delivery start-up in the San Francisco Bay area where he was President and Chief Medical Officer. While at Genentech, Dr. Shams led the clinical team in the development and approval of ranibizumab (Lucentis®). Dr. Shams received his medical degree from Dow Medical College in Karachi, Pakistan, and his PhD from the University of South Carolina in microbiology and immunology. He completed fellowships in cornea and external diseases at Harvard Medical School and histocompatibility and immunogenetics at Massachusetts General Hospital. Dr. Shams was formerly on faculty at Schepens Eye Research Institute and the Department of Ophthalmology at Harvard Medical School.